Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 118-122

  Mawer, E Barbara ^a   Walls, Janet ^b   Howell, Anthony ^b   Davies, Michael ^a   Ratcliffe, Wendy A ^c   Bundred, Nigel J ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATE;

ARTICLE; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CALCIUM URINE LEVEL; CANCER HORMONE THERAPY; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; TUMOR GROWTH; VITAMIN BLOOD LEVEL;

BONE NEOPLASMS; BREAST NEOPLASMS; CALCITRIOL; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCALCEMIA; LONGITUDINAL STUDIES; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS;

EID: 0031023922     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.118     Document Type: Article

References (29)

1. Eisman JA, Martin TJ, MacIntyre I, Moseley JM. 1979 1,25-Dihydroxyvitamin D receptor in breast cancer cells. Lancet. 2:1335-1336.
2. Colston KW, Berger U, Coombes C. 1989 Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1:188-191.
3. 3 Modulation of mammary tumor cell growth. Breast Cancer Res Treat. 27:69-81.
4. Bundred NJ, Ratcliffe WA, Walker RA, Cloey S, Morrison JM, Ratcliffe JG. 1991 Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br Med J. 303:1506-1509.
5. Horiuchi N, Caulfield MP, Fisher JEE, et al. 1987 Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science. 238:1566-1568.
6. Fraher LJ, Hodsman AB, Jonas K, et al. 1992 A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-1-34] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab. 75:417-423.
7. Hoekman K, Tjandra YI, Papapoulos SE. 1991 The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcaemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. Cancer. 68:642-45.
8. Burtis WJ, Brady JG, Orloff JJ, et al. 1989 Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med. 322:1106-1112.
9. Isales C, Carcangiu ML, Stewart AF. 1987 Hypercalcemia in breast cancer. Reassessment of the mechanism. Am J Med. 82:1143-1147.
10. Mawer EB, Gargan P, Davies M, et al. 1993 Vitamin D metabolites and parathyroid hormone related peptide in lung cancer. J Bone Miner Res. 8s1: S219 (Abstract).
11. Walls J, Ratcliffe WA, Howell A, Bundred NJ. 1994 Response to intravenous bisphosphonate therapy in hypercalcaemia patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer. 70:169-172.
12. Ratcliffe WA, Norbury S, Heath DA, Ratcliffe J. 1991 Development and validation of an immunoradiometric assay of parathyrin related protein in unextracted plasma. Clin Endocrinol (Oxf). 37:678-685.
13. Mawer EB, Hann JT, Berry JL, Davies M. 1985 Vitamin D metabolism in patients intoxicated with ergocalciferol. Clin Sci. 68:135-41.
14. 3). Clin Chim Acta. 190:199-210.
15. Davies M, Hayes ME, Yin JAL, Berry JL, Mawer EB. 1994 Abnormal synthesis of. 1:25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab. 78:1202-1207.
16. 3 by a human small-cell lung cancer cell line. J Clin Endocrinol Metab. 79:554-560.
17. Traba ML, Risco F, Hurtado J, Demiguel F, Esbrit P, Rapado A. 1990 Evidence of 1,25-dihydroxyvitamin-D synthesis by the rat Walker carcinosarcoma-256. Cancer Lett. 53:5-8.
18. 3 production. Endocrinology. 124:2057-2062.
19. Ryan EA, Reiss E. 1984 Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med. 77:501-512.
20. Budayr AA, Zysset E, Jenzer A, et al. 1994 Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res. 9:521-526.
21. Yin JJ, Taylor SD, Yoneda T, et al. 1995 Evidence that parathyroid hormone-related protein (PTHrP) causes osteolytic metastases without hypercalcemia. J Bone Miner Res. 10s1:S169 (Abstract).
22. Ikeda K, Lu C, Weir EC, Mangin M, Broadus AE. 1989 Transcriptional regulation of the parathyroid hormone-related peptide gene by glucocorticoids and vitamin D in a human C-cell line. J Biol Chem. 264:15743-15746.
23. Sebag M, Henderson J, Goltzman D, Kremer R. 1994 Regulation of parathyroid hormone-related peptide in normal human mammary epithelial cells in vitro. Am J Physiol. 267:C723-C730.
24. Garland FC, Garland CF, Gorham ED, Young JF. 1990 Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 19:614-622.
25. 3 metabolites. Cancer Res. 43:443-447.
26. Colston KW, Chander SK, Mackay AG, Coombes RC. 1992 Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 693-702.
27. 3 analogues. J Pharmacol. 178:247-250.
28. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. 1995 Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 36:83-87.
29. Elstner E, Linker-Israeli M, Said J, et al. 1995 20-epi-Vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55:2822-2830.